陈枢青的主要学术成果

如题所述

第1个回答  2016-06-05

1.厉朝龙主编,陈枢青,刘子贻,沈奇桂,赵鲁杭副主编. 《生物化学与分子生物学实验技术》. 浙江大学出版社,2000,杭州
2.厉朝龙主编,杨歧生,陈枢青副主编. 《生物化学与分子生物学》. 中国医药科技出版社,2001,北京
3.陈枢青. 用药与遗传. 《医学遗传学》。张咸宁主编,科学出版社,2002,北京.
4.陈枢青。 第11章 核酸代谢与蛋白质生物合成、第12章代谢和代谢调控总论 in 卫生部规划教材《生物化学》第五版(供药学类专业用)。吴梧桐主编。人民卫生出版社 2003年。
5.曾苏主编,姚彤炜,陈枢青 副主编。《药物代谢学》。浙江大学出版社 2004年。
6.陈枢青。第八章 遗传药理学和药物基因组学,中国科学院教材建设专家委员会规划教材《临床药理学教程》第二版魏尔清 陈红专 主编。科学出版社2007年 北京
7.陈枢青。 第3章 基因工程制药,卫生部“十一五”规划教材《生物技术制药》(供药学类专业用)。周佩主编。人民卫生出版社 2007年
8.陈枢青。 第12章核酸与核苷酸代谢、第13章 代谢和代谢调控总论 、第14章 DNA的复制与修复、第15章 转录与基因表达调控、第16章 蛋白质的生物合成, 卫生部规划教材《生物化学》第六版(供药学类专业用)。吴梧桐主编。人民卫生出版社 2007年 (其中近30篇被SCI或EI收录)
1. Yingqiu Pan; Ding Ding; Danxi Li, Shuqing Chen. Expression and Bioactivity Analysis of Staphylococcal Enterotoxin M and N. Protein Expression and Purification. 2007; 56(2): 286-292
2. Spinola M, Falvella FS, Galvan A, Pignatiello C, Leoni VP, Pastorino U, Paroni R, Chen S, Skaug V, Haugen A, Dragani TA. Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival. Lung Cancer. 2007; 55(3): 271-277
3. Chunna Yu, Su Zeng, and Shuqing Chen. In vitro evaluation for induction of traditional Chinese medicines on CYP3A4. DRUG METABOLISM REVIEWS 38: 138-138 Suppl. 3 2006
4. Shenggu Xie, Yakun Chen, Shuqing Chen and Su Zeng. Glucuronidation of flavonoids by human UGT1A3, UGT1A9 and structure-activity relationships. DRUG METABOLISM REVIEWS 38: 129-129 Suppl. 3 2006
5. Yakun Chen, Shuqing Chen, Xin Li, Xiewei Wang, and Su Zeng. Genetic Variants of Human UGT1A3: Functional Characterization and Frequency Distribution in a Chinese Han Population. Drug Metabolism and Disposition. 2006; May 31; 34:1-6
6. Mingliang Wu, Shuqing Chen, Xiaohong Wu. Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in chinese cancer patients. Medical Science Monitor. 2006, 12(5): 174-178.
7.Xue Qiao, Sun Hong-ying, Ying Yue-bin, Chen Shu-qing. Switch of regulatory domains of P-protein and T-protein from E. coli. Chinese Journal of Biochemistry and Molecular Biology. 2006, 22(4): 296-300.
8.Y.K. Chen, S.Q. Chen, X. Li, S. Zeng. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica. 2005; 35(10-11): 943-54.
9.Su Zeng, Shuqing Chen, Changxiao Liu. Introduction to 2005 Hangzhou International Conference on Drug Metabolism. Asian Journal of Drug Metabolism and Pharmacokinetics. 2005; 5(4): 243-50.
10.Ya-Kun Chen, Xin Li, Shu-Qing Chen, Su Zeng. Heterologous expression of active human uridine diphosphate glucuronosyltransferase 1A3 in Chinese hamster lung cells. World Journal of Gastroenterology. 2005;11(1):118-21.
11.Ming Rong Qian, Shu Qing Chen, Xin Li, Su Zeng. Cloning of human UGT1A4 cDNA and its expression in Bac-to-Bac system. Biochemical and Biophysical Research Communications. 2004; 319: 386-92
12.Weixing Shi, Shuqing Chen. Study on frequencies of poor metabolizers of cytochrome P450 2C19in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World Journal of Gastroenterology. 2004; 10(13): 1961-3.
13.Shuqing Chen, Sarah Vincent, David B. Wilson and Bruce Ganem. Mapping of Chorismate Mutase and Prephenate Dehydrogenase Domains in the Escherichia coli T-protein. European Journal of Biochemistry. 2003; 270(4): 757-63
14.Sarah Vincent, Shuqing Chen, David B. Wilson and Bruce Ganem. Probing the overlap of chorismate mutase and prephenate dehydrogenase sites in the Escherichia coli T-protein: a dehydrogenase-selective inhibitor. Bioorganic & Medicinal Chemistry Letters, 2002; 12(6): 929-931
15.Husain A, Chen S, Wilson DB, Ganem B, A Selective Inhibitor of Prephenate Dehydratase, Bioorganic & Medicinal Chemistry Letters. 2001; 11(18): 2485-2488
16.TW Yao, S Zeng, TW Wang, SQ Chen. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. Biomedical chromatography 2001; 15(1): 9-13
17.Chen Shu-qing, Peter J Wedlund. Correlation between cytochrome P450 2D6 (CYP2D6) phenotype and genotype. Acta Pharmacol Sin. 1999; 20(7):585-8
18.Shuqing Chen, Luhang Zhao, Xiaoping Zhao, Baiye Jin. Cytochrome P450 2C19 polymorphism and its relationship to cancer susceptibility. The 11th international conference on cytochrome P450. 1999.8.29-9.3 Sendai, Japan.
19.Chen Shu-qing, Sun Hong-ying,Zhao Lu-hang,Peter J Wedlund. Analysis of cytochrome P450 2D6 enzyme deficient allele CYP2D6T by allele-specific amplification. Progress in Biochemistry and Biophysics. 1999;26(1):90-2
20.Shuqing Chen, S. Kumar, W-H Chou, J.S. Barrett and PJ Wedlund. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in random versus selected healthy subject populations. British Journal of Clinical Pharmacology. 1997;44:303-4
21.Shuqing Chen, Wen-Hwei Chou, Robert A. Blouin, Zhongping Mao, Laurie L. Humphries, Q. Craig Meek, John R. Neill, Walter L. Martin, Lon R. Hays and Peter J. Wedlund. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clinical Pharmacology and Therapeutics. 1996; 60: 522-34
22.Shuqing Chen, Victoria King, Peter Wedlund and L. Hays. Cytochrome P450-2D6 (CYP2D6): Simplified screening for the A and B alleles and deficient enzyme expression. Clinical Pharmacology and Therapeutics. 1995; 57(2): 150
23.Peter J. Wedlund, Shuqing Chen, J.R. Neill, Q.C. Meek and W.L. Martin. Cytochrome P450-2D6 (CYP2D6) alleles in depressed patients with adverse effects. Pharmaceutical Research 1995; 12(9): 380